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ABSTRACT
Genetic devices that directly detect and respond to
intracellular concentrations of proteins are impor-
tant synthetic biology tools, supporting the design
of biological systems that target, respond to or alter
specific cellular states. Here, we develop ribozyme-
based devices that respond to protein ligands in two
eukaryotic hosts, yeast and mammalian cells, to reg-
ulate the expression of a gene of interest. Our de-
vices allow for both gene-ON and gene-OFF response
upon sensing the protein ligand. As part of our de-
sign process, we describe an in vitro characterization
pipeline for prescreening device designs to identify
promising candidates for in vivo testing. The in vivo
gene-regulatory activities in the two types of eukary-
otic cells correlate with in vitro cleavage activities
determined at different physiologically relevant mag-
nesium concentrations. Finally, localization studies
with the ligand demonstrate that ribozyme switches
respond to ligands present in the nucleus and/or
cytoplasm, providing new insight into their mecha-
nism of action. By extending the sensing capabili-
ties of this important class of gene-regulatory device,
our work supports the implementation of ribozyme-
based devices in applications requiring the detection
of protein biomarkers.
INTRODUCTION
Proteins are the primary determinants of cellular pheno-
type, and much of cellular behavior is governed by protein
concentrations and activities. Therefore, genetic devices that
directly detect and respond to intracellular concentrations
of proteins are important engineering tools. By linking pro-
tein concentrations to gene expression events, researchers
can build synthetic gene control systems that target, re-
spond to or alter specific cellular states.
Synthetic RNA switches are a class of genetic devices
that regulate target gene expression in response to user-
specified molecular inputs. They generally contain at least
two core components: a sensor component (typically an ap-
tamer that binds a small molecule or protein ligand) that de-
tects the input signal through a binding interaction and an
actuator component thatmodulates expression of the target
gene. Many such binding elements can be found in nature
(1–3) and new aptamers can be generated to target ligands
through in vitro selection strategies (4,5).
A number of RNA devices that respond to protein lig-
ands have been demonstrated in higher eukaryotes, includ-
ing mammalian cells (6–10). These protein-responsive sys-
tems have been shown to act through various mechanisms,
including translational inhibition (8,10–12), splicing regula-
tion (13) and RNAi-based gene silencing (9). However, the
protein-responsive RNA devices demonstrated to date ex-
hibit a number of functional limitations. For example, based
on the mechanism of gene regulation encoded in the switch,
the gene-regulatory device can respond to protein ligands
in the nucleus or the cytoplasm, but not both, which can
limit the applications of these existing platforms. In addi-
tion, most of the device platforms described to date uti-
lize an architecture in which ligand binding is linked to the
modulation of the regulatory component’s activity through
a singlemechanism, resulting in platforms that exhibit a sin-
gle input/output (I/O) relationship (i.e. either ON or OFF
but not both). Finally, the protein-responsive RNA devices
described to date are not readily portable among higher eu-
karyotes, simpler microorganisms and in vitro systems, lim-
iting the capability to perform rapid prototyping and device
optimization strategies (14,15).
As an alternative RNA device platform, ligand-
responsive ribozyme switches can regulate cleavage events
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in mRNAs to modulate the stability of the transcript in
response to ligand levels. A previously described framework
for constructing ribozyme-based devices provides a mod-
ular strategy for assembling this class of gene-regulatory
devices from a sensor component, comprising an RNA
aptamer, an actuator component, comprising the satellite
RNA of tobacco ringspot virus (sTRSV) hammerhead
ribozyme (HHRz) (16,17) and a transmitter component,
comprising a sequence that functionally couples the sensor
and actuator components (18). Ribozyme switches have
been used in a variety of cellular engineering applications
to date, including performing multi-input logic opera-
tions (19), supporting high-throughput enzyme evolution
strategies (20) and controlling cell fate decisions (21,22).
The ribozyme switch platform addresses a number of the
limitations associated with the protein-responsive RNA de-
vices demonstrated to date. First, the transmitter compo-
nent supports the rational design of ribozyme switches that
either repress or enhance gene expression, allowing the plat-
form to access both ON and OFF I/O relationships (15,18–
19,21). Second, switch activity and function can be tuned
through modifications to the sequence of the aptamer, ri-
bozyme, and transmitter components (18,23). Third, be-
cause their mechanism of action is independent of cell-
specific machinery, ribozyme switches exhibit conserved ac-
tivity across higher eukaryotes, microorganisms and in vitro
systems (14–15,18,23). However, ribozyme switches have
only been demonstrated to respond to small molecule lig-
ands. In addition, the precise mechanism of action of this
class of RNA device (i.e. where cleavage takes place within
the cell) and thus requirements for ligand localization for
modulating cleavage activity is not currently understood.
Here, we demonstrate the extension of the ribozyme
switch platform to the detection of protein ligands. We de-
velop two device architectures that incorporate different
structure switching mechanisms to control ribozyme cleav-
age activity as a function of ligand binding to the sensor
domain of the device. We also demonstrate that an in vitro
characterization pipeline can be used to prescreen device de-
signs to identify the most promising candidates for in vivo
testing and validation. Specifically, the in vitro screen can be
used to identify protein-responsive ribozyme switches with
gene-regulatory activities in both yeast and mammalian
cells.We observe that in vivo gene-regulatory activities in the
two types of eukaryote cells correlate with in vitro cleavage
activities determined at different, physiologically relevant
magnesium ion concentrations. Finally, localization studies
with the protein ligand demonstrate that ribozyme switches
can respond to ligands localized in the nucleus, the cyto-
plasm or both, providing new insight into the mechanism
of action of this important class of gene-regulatory devices.
MATERIALS AND METHODS
Preparation of cis-blocked RNA devices and protein ligands
for in vitro assays
Cis-blocked RNA devices transcribed from DNA tem-
plates were prepared as previously described (14). For cis-
blocked ribozyme constructs (Supplementary Table S1),
polymerase chain reaction (PCR) products were ampli-
fied from DNA templates using the forward primer T7-
fwd (5′-TTCTAATACGACTCACTATAGG) and the re-
verse primer bMS2-rev (5′-AACAAAG CTGTTTCGTC-
CTC). His-tagged-maltose binding protein-MS2 coat pro-
tein (His-MS2-MBP), gift of Rachel Green (Johns Hop-
kins University), was used in all in vitro studies with MS2-
responsive RNA devices.
In vitro surface-plasmon-resonance-based RNA-protein bind-
ing assays
Binding data was determined for the protein–RNA device
interaction by a surface-plasmon-resonance (SPR)-based
assay, using a multi-cycle kinetics approach. Interactions
were measured at several analyte concentrations as a func-
tion of time, and fit to a 1:1 binding model (24). The Bi-
acore X100 (GE Healthcare Bio-Sciences, Uppsala, Swe-
den) sensor chip surface immobilized with DNA activator
was generated as previously described (14). System prim-
ing, startup, and regeneration procedures were carried out
as previously described (14), with HBS-EP+ (GE Health-
care Bio-Sciences) used as the running buffer.
Following the startup cycles, assay cycles were performed
at several different analyte concentrations (0.1–600 nM),
with at least one cycle repeated. Ligand capture amounts
and analyte flow rates were varied in replicate binding as-
says for the same RNA device in effort to assess and min-
imize any mass transfer limitations (25,26). From first run
dissociation constant (KD) approximations, the analyte con-
centrations of subsequent runs were adjusted, where neces-
sary, such that they ranged from 0.1 × KD to 100 × KD for
a more accurate estimate of the kinetic parameters (25,26).
Each assay cycle includes a capture, association, dissoci-
ation and regeneration step. The capture and regeneration
stepswere performed as described for the startup cycles. The
association stepwas performed by an injection ofHBS-EP+
buffer containing the protein analyte over both flow cells
(FCs) for 30–90 s at 20–50 l/min. Running buffer (HBS-
EP+) was then injected over both FCs in the dissociation
step for 300–600 s at 20–50l/min. The Biacore X100 Eval-
uation Software v2.0 (GE Healthcare Bio-Sciences) was
used to process the datasets and analyze interaction kinet-
ics. The reference flow cell (FC1) data was first subtracted
from sample flow cell (FC2) to correct for injection noise,
baseline drift, nonspecific surface binding and bulk refrac-
tive index changes. This reference-subtracted (FC2-FC1)
data was further referenced to a blank injection of run-
ning buffer to account for any systematic drift occurring
over course of the assay (24,27). The double-referenced data
were fit to a 1:1 binding model for kinetic analysis (26). Re-
ported values are themean± 1 standard deviation of at least
three independent experiments.
In vitro surface-plasmon-resonance-based RNA cleavage as-
says
SPR-based RNA cleavage assays were carried out for
protein-responsive RNA devices as previously described
for small molecule-responsive RNA devices (14). The pro-
cessed sensorgram (R) was fit to a simple exponential equa-
tion R = (R0 − R∞) × (e−kdt) + R∞, where R0 (fit glob-
ally for a given replicate) is the initial SPR signal before the
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cleavage reaction, R∞ (fit locally for a given replicate) is the
residual response at the end of the cleavage reaction and kd
is the first-order RNA dissociation rate constant. RNA dis-
sociation rate constants were only quantified in the absence
of protein, as the SPR response signal from protein bind-
ing was significant, masking the RNA dissociation event re-
sponse signal. Reported values are the mean ±1 standard
deviation of at least three independent experiments.
In vitro gel-based RNA cleavage assays
Generation of radiolabeled, full-length RNA devices re-
sponsive to protein ligands and subsequent cleavage assays
to determine cleavage kinetics were carried out as previously
described for natural HHRzs and theophylline-responsive
RNA devices with minor adaptation (14). Briefly, gel-based
ribozyme cleavage assays were performed in a physiolog-
ically relevant reaction buffer (40 l) composed of 500
M MgCl2, 150 mM NaCl, 1 mM DTT and 10 mM
HEPES (pH 7.4) at 37◦C. In the reaction volume, 1–10 nM
of radiolabeled, full-length RNA generated from the cis-
blocking strategy was first incubated with 2.5MDNA ac-
tivator strand (5′-AAACAACTTTGTTTGTTTCCCCC),
for 5 min to activate the blocked RNA. The zero time-point
aliquot was taken before initiating the self-cleavage reac-
tion with the addition of MgCl2 and indicated amount of
His-MS2-MBP fusion protein. To determine kobs, the first-
order rate constant of in vitroRNAself-cleavage, the cleaved
product fraction at each time point (Ft) was fit to the single
exponential equation Ft = F0 + (F∞ − F0)× (1 – e−kobst) us-
ing GraphPad Prism 5 (GraphPad Software, La Jolla, CA),
where F0 and F∞ are the fractions cleaved before the start
of the reaction and at the reaction endpoint, respectively.
For selected MS2-responsive RNA devices, additional
cleavage assays were performed at variousMS2 protein con-
centrations to generate dose-response curves. The cleav-
age rate constant (kobs) at each MS2 protein concentration
([MS2]) was fit to the sigmoidal equation kobs = kmin + (kmax
− kmin) / (1 + [MS2] / IC50) usingGraphPad Prism 5, where
kmax and kmin are the maximum and minimum cleavage rate
constants, evaluated in the absence of and with the highest
MS2 concentration assayed, respectively (28–30). The IC50
is defined as the MS2 protein concentration at which the
cleavage rate constant is half-maximal. In all regressions,
the model fit the data well with R2 > 0.95.
Plasmid construction
All plasmids were constructed using standard molecular bi-
ology techniques. Oligonucleotides were synthesized by In-
tegrated DNA Technologies (Coralville, IA) and the Stan-
ford Protein and Nucleic Acid Facility (Stanford, CA).
Cloning enzymes, including restriction enzymes and T4
DNA ligase, were obtained fromNew England Biolabs and
Life Technologies. Cloning products were electroporated
into Escherichia coli DH10B (Life Technologies) using a
GenePulser XP system (Bio-Rad Laboratories) or trans-
formed into E. coli One Shot Top 10 (Life Technologies)
using standard methods. Clones were screened using colony
PCR and verified by sequencing (Elim Biopharmaceuticals,
Hayward, CA).
The yeast MS2 expression vector (pCS2711; Supplemen-
tary Figure S1A) was based on plasmid 14191 (Addgene,
Cambridge, MA), into which a DNA fragment encoding
an MS2-mCherry fusion protein, obtained from pCS2580,
was inserted between a TDH3 promoter and a CYC1 ter-
minator by Gateway cloning methods (31). The plasmid
14192 (Addgene) was used as the no-MS2 empty control
vector. All ribozyme-based devices and associated controls
were cloned between a yeast-enhanced green fluorescent
protein (GFP) open reading frame and ADH1 termina-
tor in pCS1748 using either Gibson cloning or restriction
enzyme-mediated cloning (AvrII/XhoI) as described previ-
ously (23) (Supplementary Figure S1B).
A standardized cloning method was developed to facili-
tate insertion of ligand-responsive devices and ligand cod-
ing regions into a single plasmid backbone thatwas compat-
ible with the construction of stable isogenic mammalian cell
lines. A DNA fragment encoding d2EGFP with a bGHpA
signal and the cytomegalovirus (CMV)-TetO2 promoter
was synthesized by GeneArt (Life Technologies) and in-
serted into pcDNA5/FRT (Life Technologies) between the
restriction sites AflII/KpnI to form pCS2304 (Supplemen-
tary Figure S1C), which contains a CMV promoter ex-
pressing d2EGFP and FRT recombinase sites compatible
with single-site, stable integration into the genome of Flp-
In T-REx human embryonic kidney 293 (HEK293) cells
(Life Technologies). A DNA fragment encoding the EF1
promoter upstream of the blue fluorescent protein (BFP)
coding region was PCR-amplified from pCS2585 (cour-
tesy Melina Mathur) using the primers EF1BFP Fwd and
EF1BFP Rev and inserted between BglII/AvrII, and the
MS2 coding region was PCR-amplified from pCS1392 us-
ing the primers No NLS A/X Fwd and MS2 A/X Rev and
inserted between XhoI/ApaI in pCS2304 to form pCS2595
(Supplementary Figure S1D).
A DNA fragment encoding 2MS2mut (MS2
V75E/A81G head-to-tail fused dimer) was synthesized by
GeneArt (Life Technologies) and inserted into pCS2595
between NotI/ApaI to form pCS2686. The coding region
of 2MS2mut was PCR-amplified from pCS2686 using the
primers NLSMS2 F and 2MS2mut R to add anN-terminal
nuclear localization sequence (NLS), and using the primers
2MS2mut F and NES MS2 R to add a C-terminal nuclear
exclusion signal (NES), and inserted into pCS2595 between
NotI/ApaI to form pCS2747 and pCS2787, respectively.
The coding region of DsRedMonomer was PCR-
amplified from pCS2359 using the primers DsRed GF
and DsRed GR, and using the primers DsRed GF and
DsRed NES R to add a C-terminal NES. The result-
ing DNA fragments were inserted into plasmids digested
with ApaI using Gibson assembly (32) to create 2MS2mut-
DsRedMonomer fusions as follows: DsRed into pCS2686
to form pCS2897, DsRed into pCS2747 to form pCS2902,
and DsRed-NES into pCS2686 to form pCS2907. The
ribozyme-based devices and associated controls (Supple-
mentary Table S1) were inserted between the AvrII/AscI
cloning sites in all plasmids (pCS2595, pCS2686, pCS2747,
pCS2787, pCS2897, pCS2902, pCS2907).
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RNA device characterization assays in yeast
All yeast strains described in this work are based onCSY22,
a previously-described W303a-derived strain with a GAL2
deletion (33). Yeast transformations were performed using
standard lithium acetatemethods (34). Cultures were grown
in synthetic complete media, 2% dextrose, YNB (Life Tech-
nologies), lacking uracil and tryptophan. Fluorescent pro-
tein expression levels were measured through flow cytom-
etry analysis. Briefly, overnight cultures were backdiluted
1:100 into fresh 3-ml cultures and grown 6 h at 30◦C. Fluo-
rescence levels of cell populations were measured on a FAC-
SAriaII Custom System (BD Biosciences, San Jose, CA)
equippedwith a 488-nm laser, with emission collected at 508
nm. Data were analyzed using FlowJo (Tree Star, Ashland,
OR). For each culture, viable cells were gated by side scat-
ter and forward scatter, and the geometric mean GFP level
of the population was recorded. For each test condition, the
population geometricmeans of three independent replicates
were averaged. These average values were then normalized
by the average GFP of cells harboring an inactive ribozyme
control (sTRSVctrl) assayed under the same conditions. Re-
ported values are normalized averages ± 1 standard devia-
tion.
Mammalian cell culture
Flp-In T-REx HEK293 cells (Life Technologies) were cul-
tured in 10 ml (10-cm dish) or 3 ml (6-cm dish) Dul-
becco’sModifiedEagle’smedium (DMEM) (Life Technolo-
gies) supplementedwith 10% fetal bovine serum (FBS) (Life
Technologies), 100 mg/l zeocin (Life Technologies) and
5 mg/l blasticidin (Life Technologies) in a humidified in-
cubator at 37◦C and 5% CO2. Cells were seeded at 2 ×
104 cells/ml and passaged regularly using 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) (Life Technolo-
gies), with media replaced every 48–72 h. Cells stably inte-
gratedwithFlp-In constructs were cultured similarly, except
the cell culture media were supplemented with 100 mg/l hy-
gromycin B (Life Technologies) and no zeocin.
Transient transfection of mammalian cell lines
Flp-In T-RExHEK293 cells were seeded at 1× 105 cells/ml
in 500 l (24-well plate), 10 ml (10-cm dish) or 400 l (8-
chambered coverglass) DMEM with 10% FBS. The cells
were transfected 21–27 h (flow cytometry assay), 48 h (cel-
lular fractionation and extraction) or 24 h (confocal mi-
croscopy) after seeding with one or two plasmids using Fu-
GENEHD (Promega,Madison,WI) according to theman-
ufacturer’s instructions. DNA and FuGENE HD were in-
cubated together in Opti-MEM in a 1:3:50 (g:l:l) ratio for
∼1 h. 500-l samples received 500 ng of DNA, 10-ml sam-
ples received 10 g of DNA and 400-l samples received
400 ng of DNA.
Stable mammalian cell line generation
Flp-In T-RExHEK293 cells were seeded at 1× 105 cells/ml
in 2 ml (6-well plate) DMEMwith 10% FBS. The cells were
cotransfected with a pcDNA5/FRT-derived plasmid and
pOG44 (Life Technologies) 24 h later in a 1:9 ratio using Fu-
GENE HD (Promega) according to the manufacturer’s in-
structions. DNA and FuGENE were incubated together in
Opti-MEM in a 1:3:50 (g:l:l) ratio for ∼1 h, with 2-ml sam-
ples receiving 2g ofDNA. The cells were resuspended 24 h
after transfection using 0.25% trypsin-EDTA and DMEM
with 10%FBS, and one quarter of the cells were used to seed
2 ml (6-well plate) DMEM with 10% FBS. The media were
replaced withDMEMwith 10%FBS, 200-mg/l hygromycin
B and 5-mg/l blasticidin 24 h later. Themedia were replaced
every 72–96 h until macroscopic colonies were visible, usu-
ally after 10–14 days. Colonies were pooled together with
0.25% trypsin-EDTA and passaged into DMEM with 10%
FBS, 100 mg/l hygromycin B and 5 mg/l blasticidin.
RNA device characterization assays in mammalian cell lines
Doxycycline was added to the growth media to derepress
the CMV-TetO2 promoter 18–28 h after seeding (30–75 min
after transfection if applicable). Fluorescence data were ob-
tained by flow cytometry 66–76 h after seeding using the
MACSQuant VYB equipped with 405-, 488- and 561-nm
lasers (Miltenyi Biotec, Bergisch Gladbach, Germany). Vi-
ability was gated by side scatter and electronic volume, and
viable cells were further gated for BFP expression (transient
transfections only). DsRed and BFP fluorescence was mea-
sured through 615/20 and 450/50 nm band-pass filters, re-
spectively.Datawere analyzed usingFlowJo (Tree Star). Re-
ported values are geometric mean ± 1 standard deviation
from at least two biological replicates. Relative BFP expres-
sion levels are reported as the geometric mean fluorescence
values normalized to those from cells harboring an inactive
ribozyme control (sTRSVctrl) assayed under the same con-
ditions.
RESULTS
Rational design of protein-responsive ribozyme switch plat-
forms
We investigated different RNA device architectures for
physically and functionally coupling the sTRSV HHRz ac-
tuator (Figure 1A) and MS2 coat protein aptamer sensor
(Figure 1B) domains. TheMS2 coat protein (35–38) was se-
lected as a ligand input because it has a well-characterized
binding interaction with RNA aptamers and due to its rela-
tively small size is expected to be present in both the nucleus
and the cytoplasm (39). Our designs leverage the fact that
the lower stem of the aptamer (Figure 1B; black backbone
bases) is only structurally conserved (35), which allows se-
quence substitutions in this region without a loss in binding
affinity.
In our first device architecture, the actuator and sensor
domains are coupled through a separate transmitter com-
ponent that mediates secondary structure switching pro-
moted by ligand binding and directed to disrupting the
HHRz core as previously described for small molecule-
responsive RNA devices (18). MS2-responsive ON ri-
bozyme switches, which up-regulated gene expression in
the presence of ligand, were built with this core-disrupting
transmitter architecture. Specifically, we modified a pre-
viously described theophylline-responsive ribozyme switch
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Figure 1. Sequence and secondary structures of the actuator (sTRSV
HHRz) and sensor (MS2 aptamer) domains. (A) The sTRSV HHRz con-
sists of a catalytic core flanked by three helices. The HHRz is integrated
into the transcript through stem III and the loop sequences auxilliary to
stems I and II are involved in mediating tertiary contacts required for cat-
alytic activity at physiological Mg2+ concentrations. The Hoogsteen U-A-
U base triple and GG base pair HHRz tertiary interactions (40) are de-
noted with boxed green and gray nucleotides, respectively. The site-specific
phosphodiester bond isomerization that results in cleavage of the RNA is
marked with a red arrow. (B) The high affinity variant of the MS2 bacte-
riophage translational operator RNA (38) used as the MS2 aptamer for
all devices in this study. Bases involved directly inMS2 protein binding are
indicated in orange, while all other bases are only structurally conserved
(35). The MS2 F5 aptamer variant has a non-canonical GA pair (brown
dotted boxes) below the bulged adenine (36). In device construction, the
aptamer is truncated to the subsequence above the bulged adenine (yellow
backbone) and grafted onto functional sequences (e.g. transmitter, HHRz
stem) to reconstitute the aptamer lower stem (black backbone). All sec-
ondary structures were predicted by RNAstructure folding software (41).
(L2b8 (18)) by replacing the theophylline aptamer with the
truncated MS2 aptamer to create MS2-A1 (Figure 2A). We
built a second MS2-responsive ribozyme switch, MS2-A2,
by altering the loop I sequence of MS2-A1 to one which
had been previously generated through a library screen and
shown to result in higher ribozyme cleavage activities (23).
Wemade a third transmitter-based device,MS2-A3, by flip-
ping the base pair of the transmitter domain immediately
proximal to the HHRz actuator to examine the role of this
transmitter base pair (a GUwobble) in cleavage and switch-
ing activity. As the sequence of the upper stem of the MS2
aptamer (Figure 1B) is variable, two GC base pairs in this
region were flipped in MS2-A2 and -A3 to avoid predicted
(41) misfolding of the RNA device (Figure 2A). Four addi-
tional device designs (MS2-A4 to -A7) were made by vary-
ing the transmitter sequence in MS2-A1 (Supplementary
Table S1) through sequential single base pair substitutions
to examine the impact of varying the minimum free ener-
gies (MFEs) associated with the gene-ON and gene-OFF
conformations (Supplementary Table S2). Two final device
designs (MS2-A8, MS2-A9) were made by shortening the
transmitter in MS2-A1 by two and four base pairs, respec-
tively, and introducing base pair substitutions to vary the
MFEs associated with each state.
The second device architecture is based on the incor-
poration of a transmitter that directs displacement of the
HHRz loop structure (Figure 2B). As the HHRz loop se-
quences are involved in catalytically mediating tertiary in-
teractions (42), we hypothesized that transmitter designs
that modulated loop base pairing can also control cleav-
age activity of the RNA device. Both MS2-responsive ON
and OFF ribozyme switches were designed with this loop-
disrupting transmitter architecture. We created an OFF
switch design, MS2-B1, by integrating the truncated MS2
aptamer with a three base pair transmitter into loop I (Fig-
ure 2B). The HHRz loop I integration point was selected
based on control experiments indicating that this integra-
tion point retained high in vitro cleavage activity (data not
shown). The transmitter is designed to Watson–Crick base
pair with loop I bases in the MFE structure, thereby dis-
rupting the cleavage-mediating loop tertiary interactions
(Figure 2B). MS2 binding stabilizes a suboptimal structure
in which the transmitter sequence base pairs to form the
stem of the aptamer, freeing the loop I nucleotides to par-
ticipate in cleavage-mediating tertiary interactions. In con-
trast, the ON switch loop-displacing designs incorporate a
single base pair transmitter and variant MS2 aptamer to
modulate HHRz loop II structure. The MS2 F5 aptamer
(KD ∼2 nM) was used in the design of these switches, which
has a GC base pair in the stem mutated to GA (Figure 1B).
The crystal structure of the F5 aptamer bound with its lig-
and shows that the GA nucleotides form a non-canonical
base pair (37). We used this information to create an ON
switch design, MS2-B2, by coupling the F5 aptamer se-
quence up to the GA base pair directly to stem II of the
sTRSV HHRz, such that the GA of the aptamer replaced
L2.1G and L2.4A of loop II (Figure 2C). We hypothesized
that MS2 protein binding will cause the GA non-canonical
pair to form, thereby closing loop II and inhibiting cleavage
activity (Figure 2C). We built two additional ON switch de-
signs, MS2-B3 and -B4, by altering the loop I sequence of
MS2-B2 to non-natural sequences that had been previously
shown to result in higher cleavage activities (23).
In vitro characterization assays support a rapid screen for
identifying candidate protein-responsive ribozyme switches
for in vivo testing
As part of the design process, numerous design variants are
developed for each device architecture to increase the like-
lihood of arriving at a device design that exhibits desired
gene-regulatory properties in vivo. Given the time associated
with cloning and characterizing individual variants, a rapid
way to prescreen designs for the most promising candidates
is desirable. Recent studies have demonstrated that in vitro
measured parameters, such as cleavage rates, can be good
predictors of ribozyme switch function in vivo (14). Thus,
we sought to develop and validate a set of in vitro assays for
rapid characterization of key device parameters that can be
used to prescreen ribozyme-based device designs prior to
testing in vivo (Figure 3A).
To measure cleavage kinetics of the ribozyme-based de-
vices, we leveraged a recently developed SPR-based assay
for quantification of cleavage rate constants (14). In this
method, RNA devices are captured onto the sensor surface,
the cleavage reaction is initiated by addition of magnesium
ions (Mg2+), and separation of the 3′ cleavage product from
the sensor surface is monitored with decreasing SPR signal
(Supplementary Figure S2). The kinetics of the SPR signal
decrease during the cleavage reaction are fit to a one phase
exponential decay equation. The fit RNA dissociation rate
constant (kd) is reflective of the RNA cleavage rate constant
(14). We applied the SPR-based cleavage assay to measure
the RNA dissociation rate constants (kd) of theMS2-A and
-B series devices in the absence and presence of 500 M
MgCl2. A previously characterized device, L2b8, was run
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Figure 2. Structure switching designs of MS2-responsive RNA devices. Nucleotides that comprise the aptamer sensor, HHRz actuator and transmitter
components are colored yellow, blue and red, respectively. In each panel the structure on the left is the MFE structure predicted by RNAstructure. (A)
MS2-responsive transmitter-based RNA devices that utilize a secondary structure changing mechanism directed to disrupting the HHRz core (MS2-A).
Predicted secondary structures of the active HHRz conformation with unformedMS2 aptamer (gene-OFF state, left) and the inactive HHRz conformation
with formedMS2 aptamer (gene-ON state, right), bound with MS2 coat protein (orange) are shown. The sequence for the MS2-A1 RNA device is shown;
brown dotted boxes denote sequence variations of MS2-A2 and MS2-A3 RNA devices, differing primarily in HHRz loop I and transmitter sequences,
respectively. (B) MS2-responsive transmitter-based OFF switch RNA device with HHRz loop secondary structure changing mechanism (MS2-B1). In
the MFE secondary structure both HHRz and aptamer are not formed (gene-ON state, left). In the active conformation both HHRz and aptamer are
formed, shown bound with MS2 coat protein (gene-OFF state, right). (C) MS2-responsive transmitter-based ON switch RNA devices with HHRz loop
secondary structure changing mechanism (MS2-B2, -B3, -B4). The HHRz structure is formed, but aptamer structure is not in the MFE structure (gene-
OFF state, left). In the inactive ribozyme conformation, aptamer is formed and bound, and HHRz structure is disrupted (gene-ON state, right). These
devices incorporate the MS2 aptamer variant containing a noncanonical GA pair (red text). The sequence for the MS2-B2 device is shown, brown dotted
boxes denote sequence variations of the MS2-B3 and MS2-B4 devices, differeing in their HHRz loop I sequence.
as a benchmark to set a cutoff for identifying devices with
cleavage activities expected to result in desired in vivo gene-
regulatory activities. RNAdissociation rate constants deter-
mined in the absence of MgCl2 were all <0.01 min−1 (data
not shown), indicating that the devices exhibit insignificant
cleavage activity levels in the absence of Mg2+ (Figure 3B).
The kd values in the presence of MgCl2 ranged from near
background (0.03min−1,MS2-A4) to∼10× higher than the
benchmark control (1.0 min−1, MS2-A2) (Figure 3B). The
devices MS2-A1, -A2, -A3, -A7, -A8 and -B3 exhibit cleav-
age activities equal to or greater than the benchmark con-
trol and thus were subjected to additional in vitro character-
ization of binding properties. We chose three additional de-
vices (MS2-B1, -B2 and -B4) to carry forward into binding
characterization, including the OFF switch, which exhib-
ited a relatively low kd (0.06 min−1), and the devices with
the MS2 F5 aptamer variant.
We characterized the binding properties of the selected
MS2-A and -B devices in a recently developed SPR-based
binding assay (43). Protein binding and dissociation to
RNA devices captured onto the sensor surface are moni-
tored in real time as an increase and decrease in SPR sig-
nal, respectively. The kinetics are fit to a 1:1 binding model
to calculate the protein binding on- and off-rate constants,
kon and koff, respectively. The dissociation constant (KD) is
calculated from ratios of koff and kon assayed at several lig-
and concentrations (24) (Figure 3C, Supplementary Figure
S3) (26). The MS2-A and -B device dissociation constants
span nearly three orders of magnitude from∼6 to∼600 nM
(Figure 3D, Supplementary Figure S3) and provide insight
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Figure 3. In vitro screening of protein-responsive RNA device cleavage and binding activities. (A) Process flowchart for development of protein-responsive
RNA devices. Candidate RNA devices are first screened in vitro by rapid SPR-based assays for RNA cleavage activity, and then for ligand binding activity
before in vivo testing. (B) SPR-based RNA dissociation rate constants for MS2-A andMS2-B RNA devices. Reactions were performed at 25◦C, in 500 M
MgCl2, 150 mM NaCl and 10 mM HEPES (pH 7.4). Reported values are the mean ± SD of at least three independent assays. RNA device dissociation
constants determined in absence of MgCl2 were all <0.01 min−1. (C–F) MS2 protein binding characterization of MS2-A and MS2-B RNA devices. (C)
Representative SPR sensorgrams for the MS2-B1 RNA device. Overlaid in the plot is the association and dissociation portion of the sensorgrams from
MS2 protein at six different concentrations (121.5, 40.5, 13.5, 4.5, 1.5, 0.5 nM). Representative sensorgrams for other RNA devices are presented in
Supplementary Figure S3. Dissociation constants (KD; (D)) for each RNA device are fit by a 1:1 kinetic binding model, taking the ratio of the off-rate
constant (koff; (E)) and on-rate constant (kon; (F)). Reported are the mean ± SD from at least three independent assays.
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into the mapping of performance properties on device de-
signs. For example, the relatively highKD, and low kon of the
MS2-B1 device (Figure 3DandF)may be due to the shorter,
three base-pair lower stem of the aptamer within this device
(Figure 2B) allowing fewer protein-binding contacts (35,44–
45), compared to the four base-pair stem found in the other
devices (Figure 2A and C) (44,46). The MS2-B2, -B3 and
-B4 devices contain the MS2 F5 aptamer variant and differ
by their loop I sequence. While their measured dissociation
constants are similar (250 ± 50 nM) (Figure 3D), the MS2-
B3 device exhibits lower koff and kon rates (Figure 3E and
F). The data indicate that theMS2-B2 and -B4 devices have
aptamer-formed structures with greater stabilities than the
MS2-B3 device (Supplementary Table S2).
The SPR-based assay cannot be used to measure the im-
pact of ligand binding on cleavage activity by quantifying
the device cleavage activity in the presence of protein ligand,
as the signal change due to protein association/dissociation
and RNA dissociation are not easily separable. Therefore,
as a proxy for device sensitivity to ligand, we used the KD
to characterize device binding in comparison to KD of ap-
tamers that have been successfully utilized within in vivo
functioningRNAdevices. All the characterizedMS2-A and
-B devices exhibit greater ligand affinities (Figure 3D; KD<
1 M) than previously developed ligand-responsive RNA
devices (18,47). Thus, based on the in vitro screen the MS2-
A1, -A2, -A3, -A7, -A8, -B1 and -B3 devices are identified
as good candidates for subsequent in vivo testing.
Protein-responsive ribozyme switches exhibit ON and OFF
activities in yeast cells
We characterized the in vivo activity of the ribozyme-based
devices identified in the in vitro screen in a yeast host. Gene-
regulatory activities of the ribozyme switches were charac-
terized by placing the devices and associated controls in the
3′ untranslated region (UTR) of a fluorescent reporter pro-
tein (GFP) (Figure 4A). Device activities were measured
as the mean fluorescent levels of cells harboring the indi-
cated constructs in the absence and presence of MS2. The
high-protein ligand condition was achieved by transform-
ing aMS2 expression construct, encoding the expression of
the MS2 coat protein fused to a mCherry protein, into the
yeast cells. The no-protein ligand condition was achieved by
transforming an empty plasmid, not encoding MS2 expres-
sion, into the yeast cells.
Ribozyme switch activities were characterized in yeast
through flow cytometry analysis. An inactiveHHRz control
(sTRSVctrl) exhibited high GFP levels in the presence and
absence of MS2, which we used to set the maximum GFP
level. A wild-type HHRz (sTRSV) reduced gene expression
to <5% of that observed from the inactive HHRz control,
consistent with efficient ribozyme cleavage in vivo. The sub-
set of MS2-responsive ribozyme switches tested in yeast ex-
hibited significant changes in GFP levels in the presence
and absence of MS2 (Figure 4B). The devices spanned a
wide range of expression levels, and exhibited bothON- and
OFF-switch activities. TheON switches exhibited a range of
stringencies (basal expression levels in the absence of MS2)
and exhibited activation ratios (ratio of expression in the
presence and absence of MS2) up to 4-fold for ON switch
MS2-A1, which switched from 20 to 97% of the maximal
GFP level. The OFF switch MS2-B1 exhibited a 4.1-fold
decrease in expression in the presence of MS2, spanning a
range between 55 and 13% of maximal GFP levels. Non-
switching control devices did not exhibit gene knockdown
activity or responsiveness toMS2 under identical assay con-
ditions (Supplementary Figure S4A), indicating that the ob-
served gene-regulatory activity is due to ribozyme cleavage
and modulation of cleavage through ligand binding rather
than nonspecific effects. These results indicate that the in
vitro screen was effective at identifying switches with in vivo
gene-regulatory activities.
Protein-responsive ribozyme switches exhibit ON and OFF
activities in mammalian cells
We also tested the in vitro identified MS2-responsive ri-
bozyme switch designs for gene-regulatory and ligand-
responsive activities in a human cell line. A ribozyme switch
characterization construct was designed in which the ri-
bozyme switches and non-switch controls were placed in the
3′ UTR of a reporter gene encoding BFP (Figure 5A). A
doxycycline-inducible expression cassette for MS2 was lo-
cated on the same plasmid, in which MS2 expression was
under the control of a CMV promoter with two down-
stream tetracycline operator (TetO) sites (CMV-TetO2). All
constructs were characterized in a Flp-In T-REx HEK293
cell line, which stably expresses the tetracycline repressor
(TetR). Thus, transcription of the protein ligand is inhibited
by TetR and the addition of doxycycline to the cell culture
media activates transcription of the protein ligand.
Ribozyme switch designs were initially characterized
through transient transfection of the characterization con-
struct into the Flp-In T-REx HEK293 cell line and subse-
quent flow cytometry analysis. The data demonstrate that
the different switch designs exhibit different gene-regulatory
properties. For example, the transmitter designs (MS2-A)
exhibited low to moderate levels of gene knockdown activ-
ity (Figure 5B). Three of the designs,MS2-A2, -A3 and -A7,
exhibited increases in BFP levels (ranging from 1.3- to 1.8-
fold) in response to doxycycline-induced MS2 expression
(Figure 5B), with MS2-A2 exhibiting the highest switching
activity of all tested designs. Both of the loop-transmitter
designs (MS2-B) exhibited gene knockdown activity and
achieved both ON and OFF responses to MS2 (Figure
5B), withMS2-B1 exhibiting a 1.4-fold reduction andMS2-
B3 exhibiting a 1.6-fold increase in BFP levels in response
to MS2 expression. As in the yeast assay (Supplementary
Figure S4A), non-switching controls did not exhibit gene
knockdown activity or responsiveness to MS2 under iden-
tical assay conditions (Supplementary Figure S4B). Taken
together, these results indicate that protein-responsive ri-
bozyme switches can exhibit activities in both yeast and
mammalian cells.
AnMS2 variant results in improved switch response to ligand
We next examined whether optimization of the protein lig-
and can improve the ligand sensitivity of the designs that
exhibited moderate levels of switching in the initial charac-
terization assay. MS2 binds to its aptamer in the dimerized
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Figure 4. In vivo activity of protein-responsive ribozyme switches in yeast cells. (A) Schematic of the protein-responsive ribozyme switch characterization
system for yeast. An expression construct encoding the ribozyme switch in the 3′ UTR of a fluorescent reporter (GFP) is encoded on a low-copy plasmid.
A separate low-copy plasmid encodes the expression of the protein ligand (or an empty control). (B) Gene-regulatory activity of MS2-responsive ribozyme
switches in yeast. (C) Gene-regulatory activity of optimized ribozyme switch (MS2-A11) in yeast. Relative GFP levels are reported for cells harboring
the indicated ribozyme switch constructs or controls in the absence and presence of MS2. Reported values are the geometric mean ± SD from biological
triplicates and normalized to the non-cleaving control (sTRSVctrl).
form (48), and once bound will multimerize to form a cap-
sid (49).We hypothesized that multimerization of the ligand
may negatively impact the activity of the ribozyme switches.
Thus, we examined the switch response to an alternative ver-
sion of theMS2 ligand, a fused dimer containing two amino
acid substitutions (V75E and A81G) to prevent multimer-
ization (50). As the MS2 monomer must dimerize to bind
to the aptamer (48), expressing the protein as a fused dimer
roughly doubles the effective ligand concentration.
We assayed a subset of ribozyme switch designs that re-
sponded to MS2 in our initial screening experiments (Fig-
ure 5B) for sensitivity to the fused dimer MS2 variant us-
ing the previously described in vivo characterization system
(Figure 5A).We performed the characterization assays with
the optimized MS2 ligand (2MS2mut) similarly to our ini-
tial experiments in the Flp-In T-RExHEK293 cell line. Our
results indicate that all examined switches were equally or
more responsive to 2MS2mut than to MS2 (Figure 5C).
MS2-B3 exhibited the highest increase in BFP levels in re-
sponse to 2MS2mut (3.6-fold), while MS2-B1 exhibited the
greatest decrease (3.8-fold). The observed increase in sensi-
tivity to 2MS2mut is likely due to the lack of multimeriza-
tion and the increased effective ligand concentration.
Based on the results of these experiments, we explored
additional improvements to the switch designs. MS2-A2
differs from MS2-A1 in the sequence of loop I, which we
hypothesized may result in the observed increase in gene
knockdown and switching activities for MS2-A2. Thus, we
modified the designs of MS2-A3 and -A7 by changing the
loop I sequence to that of MS2-A2, generating MS2-A10
and -A11, respectively. We assayed these new designs with
the 2MS2mut ligand (Figure 5C). The data indicate that
MS2-A10 and -A11 exhibited increased gene knockdown
and switching activities relative to MS2-A3 and -A7. MS2-
A11 exhibited the greatest response to ligand (4.1-fold) of
all ON switches tested in the human cell line. MS2-A11 also
exhibited improved gene knockdown and switching activi-
ties in the yeast host (8.5-fold activation in response toMS2;
Figure 4C). These results demonstrate protein-responsive
ribozyme switches that exhibit high gene-regulatory activ-
ities in response to ligand in a human cell line.
RNA device gene-regulatory activities in yeast and mam-
malian hosts correlate with in vitro cleavage activities at dif-
ferent Mg2+ concentrations
By prototyping the MS2-A and MS2-B devices by their in
vitro SPR-determined cleavage and binding activities (Fig-
ure 3), we identified candidate devices that functioned in
yeast (Figure 4) and mammalian (Figure 5) cells. However,
the in vivo gene-regulatory activities of the devices in yeast
and mammalian hosts were not significantly correlated to
each other or the SPR-determined cleavage activities (kd)
(Supplementary Figure S5). To examine the cause of this
discrepancy, we quantified in vitro cleavage kinetics on a
subset of MS2-A and MS2-B devices in the absence and
presence of MS2 protein through a gel-based cleavage as-
say.
The gel-based cleavage assays were performed on radio-
labeled transcripts at physiologically relevant reaction con-
ditions at 37◦C in the presence and absence of 2 M MS2
protein (Figure 6A, Supplementary Figure S6). The cleav-
age rate constants for the theophylline-responsive control
device (L2b8) were comparable in the absence and presence
of MS2 protein, indicating that MS2 protein has no non-
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Figure 5. In vivo activity of protein-responsive ribozyme switches in HEK293 cells. (A) Schematic of the protein-responsive ribozyme switch characteri-
zation system for human cells. The first construct encodes the expression of the ribozyme switch in the 3′ UTR of a fluorescent reporter (BFP) from a
constitutive promoter. The second construct encodes the expression of the protein ligand from a tetracycline-responsive CMV-TetO2 promoter. Both ex-
pression constructs are placed on a single plasmid, which is transfected into a Flp-In T-RExHEK293 cell line that stably expresses TetR. TetR repression is
relieved by the addition of doxycycline. (B) Gene-regulatory activity of MS2-responsive ribozyme switches in human cells. Relative BFP levels are reported
for transiently transfected cells harboring the indicated ribozyme switch constructs or controls in the absence and presence of MS2 (1 mg/l doxycycline).
(C) Gene-regulatory activity of MS2-responsive ribozyme switches to optimized ligand in human cells. Relative BFP levels are reported for transiently
transfected constructs encoding ribozyme switch sequences cotransfected with a transfection control plasmid. Reported values are the geometric mean ±
SD from biological duplicates and normalized to the non-cleaving control (sTRSVctrl).
specific effect on the cleavage activity. In contrast, for al-
most all the MS2-responsive ON switches, kobs values mea-
sured in the presence of MS2 protein were lower than those
measured in the absence of MS2 protein, indicating that
MS2 protein binding to the aptamer shifts the distribution
between the two functional conformations to the ribozyme-
inactive state, resulting in slower cleavage activity as ex-
pected. For the OFF switch (MS2-B1), kobs in the pres-
ence of MS2 protein is higher, indicating that MS2 pro-
tein binding shifts the conformational distribution toward
the ribozyme-active state, resulting in faster cleavage activ-
ity as expected. The MS2-A8 device cleavage activity (kobs)
slightly increases, from 0.08 to 0.10 min−1 in the presence of
MS2 protein, supporting the observed OFF-switch behav-
ior in yeast (Figure 4B). We compared the corresponding
cleavage time constants (kobs−1) to the yeast gene-regulatory
activities (Figure 4B; ‘NoMS2’ and ‘+MS2’ condition). The
cleavage time constants and in vivo yeast gene-regulatory
activities exhibit a strong linear correlation (Figure 6B;
Pearson product-moment correlation coefficient (Pearson
r): 0.89). The in vivo mammalian gene-regulatory activities
(Figure 5C) also correlated to the cleavage time constants,
but this correlation was not significant at a P-value of 0.01
(Supplementary Figure S7; Pearson r: 0.58). These results
suggest that the in vitro gel-based cleavage assay conditions
are more reflective of in vivo RNA device cleavage in yeast
cells than mammalian cells.
The observed reduction in ribozyme-based device cleav-
age activity in the presence of MS2 supports the proposed
device mechanism of gene regulation. Gel-based cleavage
assays were performed on two RNA devices, MS2-A1 and
-A2, over a range of MS2 protein concentrations to fur-
ther characterize the protein ligand-responsiveness of de-
vice cleavage activity (Supplementary Figures S8 and S9).
As previously observed for allosteric ribozymes, the depen-
dence of kobs onMS2 concentration is well characterized by
a sigmoidal, three-parameter logistic equation (Figure 6C
and D) (28–30). The IC50, or MS2 protein concentration at
which the cleavage rate constant is half-maximal, is deter-
mined as 63 ± 19 nM and 19 ± 4 nM for MS2-A1 and -A2
devices, respectively. These IC50 values are ∼2.5× higher,
but on the same order of magnitude as the SPR-determined
KD for MS2-A1 (Figure 3C; 25 ± 6 nM) and -A2 (Figure
6D; 6 ± 3 nM), which supports the use of the KD values as
a proxy for ligand-responsiveness of device designs.
The results suggest that our in vitro cleavage assay condi-
tions are reflective of device cleavage activity in yeast cells,
and to a much lesser extent to the cleavage activity in mam-
malian cells. While there is a multitude of physiological
differences between the hosts that may affect RNA device
cleavage and/or cleavage-induced gene regulation, we inves-
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Figure 6. In vitro gel-based cleavage activity characterizations of protein-responsive RNA devices. (A) Cleavage rate constants for MS2-responsive RNA
devices at 500 M MgCl2. Gel-based cleavage assays were performed at 37◦C in 500 M MgCl2, 150 mM NaCl, 1 mM DTT and 10 mM HEPES (pH
7.4). Cleavage rate constants (kobs) are determined by one phase exponential fit (R2 > 0.99) of the cleavage kinetics of each assay (Supplementary Figure
S6). Reported kobs are the mean ± SD of at least three independent cleavage assays performed for each device at the indicated ligand concentrations. (B)
Correlation analysis of RNA device in vivo gene-regulatory activities in yeast (Figure 4; ‘No MS2’ and ‘+MS2’ conditions) and in vitro cleavage activity
(cleavage time constant; kobs−1). Pearson correlation coefficient (r): 0.89, slope = 0.006 ± 0.0007. (C and D) Concentration dependence of cleavage rate
constants for (C) MS2-A1 and (D) MS2-A2 RNA devices. Cleavage rate constants (kobs) were determined at MS2 protein concentrations spanning five
orders of magnitude and fit to a three-parameter logistic equation (R2 > 0.96). Dotted lines indicate IC50, the MS2 protein concentration at which the
RNA device cleavage rate constant is halfway between maximum and minimum values. Cleavage rate constants reported at each MS2 concentration are
the mean ± SD of at least three independent assays. Representative cleavage kinetics are presented in Supplementary Figure S8 and Supplementary Figure
S9. (E) Cleavage rate constants for MS2-responsive RNA devices at 200 MMgCl2. Gel-based cleavage assays were performed at 37◦C in 200 MMgCl2,
150 mM NaCl, 1 mM DTT and 10 mM HEPES (pH 7.4). Cleavage rate constants (kobs) are reported as the mean ± SD from fit of cleavage kinetics
(Supplementary Figure S10) to one phase exponential (R2 > 0.99) of at least three independent assays for each device. (F) Correlation analysis of RNA
device in vivo basal level gene-regulatory activities in mammalian cells (Figure 5; ‘NoMS2’ condition) and in vitro cleavage activity (cleavage time constant;
kobs−1). Pearson correlation coefficient (r): 0.97, slope = 0.008 ± 0.001.
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tigated the effect of Mg2+ concentration. Mg2+ plays an im-
portant role inRNA secondary structure formation and ter-
tiary interactions in the HHRz cleavage reaction (40,42,51–
52). Researchers have observed the dependence of cleav-
age activity (kobs) on Mg2+ varies between different HHRz
species (53). Thus, it is plausible that the Mg2+-dependent
kobs profile could vary between different RNA device de-
signs. Intracellular, cytosolic free Mg2+, in most cell types,
is generally estimated between 500 M and 1 mM (54–59).
However, the lower range estimates can be as low as 50 M
(60) and 200 M (61,62). Thus, it is conceivable that there
is significant variation in intracellular Mg2+ concentrations
between the yeast and mammalian hosts, which leads to
differential RNA device cleavage and gene-regulatory pat-
terns.
To investigate the Mg2+ dependence on RNA device
cleavage activities, we examined kobs at a lower physiological
Mg2+ concentration. Gel-based cleavage assays were per-
formed using the same conditions as above, except at 200
MMgCl2 in the absence of MS2 protein (Figure 6E, Sup-
plementary Figure S10). We find the RNA device rank or-
der is the same in terms of increasing cleavage time constant
(at 200 M MgCl2) and in vivo mammalian basal gene-
regulatory activities (Figure 5C). Furthermore, the cleav-
age time constants measured at 200 M MgCl2 exhibit a
strong linear correlation when compared to in vivo mam-
malian basal gene-regulatory activities (Figure 6F; Pear-
son r: 0.97), but not when compared to those same values
for yeast (Supplementary Figure S11; r: −0.29). Taken to-
gether, our results imply that the in vivo gene-regulatory ac-
tivities in both yeast and mammalian eukaryotic hosts can
be predicted by measuring cleavage activities at different,
physiologically relevant Mg2+ conditions.
Ribozyme switches respond to protein ligand in both the nu-
cleus and cytoplasm
Understanding the ligand localization requirements of an
RNA device is critical to its downstream implementation in
regulatory networks. The device may be unresponsive if the
ligand of interest is localized to a cellular compartment that
is not compatible with its mechanism of action. Protein lig-
ands are often primarily localized to either the nucleus or
cytoplasm, such that all of the protein-responsive RNA de-
vices developed to date are limited to responding to ligands
localized to one of these two compartments (6,8–11). In the
case of a ribozyme ON switch (i.e. ligand binding prevents
ribozyme cleavage), if the ribozyme cleaves prior to export
from the nucleus and the ligand is present in only the cy-
toplasm, the switch will be unresponsive to ligand. Alter-
natively, if the ligand is present in only the nucleus, the ri-
bozyme may cleave after export to the cytoplasm, thereby
limiting the switch response to the ligand. We utilized di-
rected localization of the protein ligand to investigate the
impact of ligand localization on ribozyme switch activity
and shed insight into the mechanism of action of the ri-
bozyme switch, such as when the ribozyme cleaves relative
to transcription, nuclear export and translation.
The MS2 (14 kDa) and 2MS2mut (28 kDa) ligands
are expected to be present in both the nucleus and the
cytoplasm as they are small enough to passively diffuse
through the nuclear pore without the aid of any nuclear
transport machinery (63). To control localization of the
protein ligand, we created 2MS2mut variants with either
an N-terminal nuclear localization sequence derived from
Simian virus 40 (SV40) (64) (NLS-2MS2mut) or a C-
terminal nuclear export sequence derived from protein ki-
nase A inhibitor a (PKIa) (65) (2MS2mut-NES). West-
ern blotting and immunostaining data indicated that al-
though 2MS2mut-NES was effectively localized to the cy-
toplasm, the NLS-2MS2mut was present in both the cy-
toplasm and the nucleus (Supplementary Figure S12). We
hypothesized that although NLS-2MS2mut was being ac-
tively transported into the nucleus, its small size allowed
it to passively diffuse out of the nucleus and accumulate
in the cytoplasm. To achieve more effective localization
of the protein ligand, we created a 2MS2mut-DsRed fu-
sion protein to increase ligand size and modified it with ei-
ther the N-terminal NLS (NLS-2MS2mut-DsRed) or the
C-terminal NES (2MS2mut-DsRed-NES). Expression of
the fusion proteins was under the control of a doxycycline-
inducible CMV-TetO2 promoter and this construct was
placed on a plasmid that also encoded constitutive expres-
sion of a BFP reporter, which served as an unlocalized
reporter protein control. We transiently transfected Flp-
In T-REx HEK293 cells with plasmids encoding expres-
sion of each of the protein variants and imaged the cells
using confocal fluorescence microscopy (Supplementary
Figure S13). The data demonstrate that while 2MS2mut-
DsRed exhibited the same distribution throughout the cell
as BFP,NLS-2MS2mut-DsRedwas localized to the nucleus
and 2MS2mut-DsRed-NESwas localized to the cytoplasm.
Thus, the results indicate that the variants of the fusion pro-
tein localized to the expected subcellular locations.
We next examined the effects of protein ligand local-
ization on the gene-regulatory activities of the ribozyme
switches. The activities of the ON (MS2-A11) and OFF
(MS2-B1) switches that exhibited the highest activation ra-
tios were examined with the unlocalized, nuclear-localized
and cytoplasmic-localized versions of the ligand in a sta-
ble expression assay. The expression constructs were inte-
grated into a Flp-In T-REx HEK293 cell line to gener-
ate stable cell lines. Ribozyme switches responded to the
nuclear-localized ligand to a lesser extent than to either
the unlocalized or cytoplasmic-localized ligands, which re-
sult in similar response levels (MS2-A11: NLS, 3.6-fold;
unlocalized, 6.4-fold; NES, 6.5-fold; MS2-B1: NLS, 2.8-
fold; unlocalized, 4.6-fold;NES, 4.3-fold) (Figure 7A). Both
ribozyme switches responded similarly to the 2MS2mut-
DsRed ligand as to 2MS2mut ligand (Supplementary Fig-
ure S14), indicating that fusion to the fluorescent reporter
did not impact switch response. The lower response ob-
served for the nuclear-localized ligand may be explained by
either a specific effect of nuclear localization of the ligand
on switch response or a reduced steady-state level of the
nuclear-localized protein compared to the other variants.
To examine the relationship between ligand expression
level and switch response for the three localization variants
of 2MS2mut-DsRed, we measured the gene-regulatory ac-
tivities of both switches in stable cell lines grown across a
range of doxycycline concentrations resulting in a range of
protein ligand levels (Figure 7B, C, Supplementary Figure
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Figure 7. Effect of ligand localization on protein-responsive ribozyme switch activity. (A) Gene-regulatory activity of MS2-responsive ribozyme switches
in human cells for unlocalized (2MS2mut-DsRed), nuclear localized (NLS-2MS2mut-DsRed) and cytoplasmic localized (2MS2mut-DsRed-NES) ligand.
Reported BFP values are the geometric mean ± SD from biological duplicates and normalized to the non-cleaving control (sTRSVctrl). (B and C) Gene-
regulatory activity of (B) MS2-A11 and (C) MS2-B1 for unlocalized, nuclear localized and cytoplasmic localized ligand as a function of doxycycline
concentration (0–50 g/l). Reported BFP values are the geometric mean± SD from biological duplicates, exceptMS2-B1 at 0.8 g/l, unlocalized (singlet).
(D and E) Gene-regulatory activity of (D) MS2-A11 and (E) MS2-B1 for unlocalized, nuclear localized and cytoplasmic localized ligand as a function of
ligand concentration. Ligand levels are reported as the DsRed geometric mean ± SD from biological duplicates, except MS2-B1 at 0.8 g/l, unlocalized
(singlet). BFP and DsRed levels are reported for stably integrated constructs encoding the indicated ribozyme switch and ligand expression cassettes at the
indicated doxycycline or ligand levels.
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S15). The data indicate that MS2-A11 and MS2-B1 exhib-
ited a lower response to the nuclear-localized ligand than to
either the unlocalized or cytoplasmic-localized ligand vari-
ants at all doxycycline concentrations tested (Figure 7B and
C). However, a comparison of gene-regulatory activities at
identical concentrations of ligand (i.e. DsRed fluorescence
levels) reveals that the three protein variants yielded simi-
lar quantitative relationships between switch activities and
ligand levels (Figure 7D and E). These results indicate that
ribozyme switch response is primarily dependent on protein
ligand levels, with ligand localization having only a small
effect, such that nuclear and cytoplasmic localization of lig-
and are each sufficient for achieving a substantial switch re-
sponse.
DISCUSSION
We have described a method for generating RNA devices
that respond to protein inputs that are located in the nucleus
and/or cytoplasm. We further describe an in vitro screening
strategy for identifying candidates for in vivo implementa-
tion based on binding and cleavage parameters. Using our
strategy, we have developed both ON and OFF ribozyme
switches responsive to theMS2 coat protein that exhibit ac-
tivation ratios as high as 6.5- and 8.5-fold in mammalian
and yeast cells, respectively. We observed the in vivo gene-
regulatory activities of the RNA devices in mammalian and
yeast cells to be correlated with in vitro cleavage rate activi-
ties assayed at different, physiologically relevant Mg2+ con-
centrations, 0.2 and 0.5 mM, respectively.
The RNA device design methodology previously estab-
lished for small molecule-responsive ribozyme-based de-
vices (18) was utilized in the development of the MS2-A
series ON switches (Figure 2A). Our designs integrate the
transmitter into loop II of the sTRSV HHRz (Figure 1A),
which is predicted to result in a GU wobble base pairing
of the second and third nucleotide bases in loop II (Fig-
ure 2A) (41). As these bases form important tertiary con-
tacts in the sTRSV HHRz (Figure 1A) (40), we hypothe-
sized that transmitter sequences that destabilize this unde-
sired GU wobble pair would lead to higher cleavage activ-
ity and more stringent gene-regulatory control. Analysis of
previously developed small molecule-responsive RNA de-
vices with rationally designed (18) and selected transmit-
ter sequences (23) is consistent with this hypothesis. In this
study, we observed that the identity of the first base pair of
the transmitter sequence immediately following loop II is
significant to cleavage activity. For example, MS2-A series
devices with a GU/UG wobble pair (MS2-A1, -A2, -A3,
-A7, -A8) have significantly greater cleavage activity than
devices with a GC Watson–Crick base pair at this posi-
tion (MS2-A4, -A5, -A6) (Figure 3A). We suspect that in
contrast to the Watson–Crick base pair, the wobble pair
in the first transmitter position destabilizes undesired base
pairings of the second and third HHRz loop II nucleotide
bases, retaining important tertiary interactions that ulti-
mately results in higher in vitro cleavage and lower in vivo
gene-regulatory activities.
Our study also describes a novel RNA device transmit-
ter design methodology for creating both ON and OFF
switches in mammalian and yeast cells that involve mod-
ulating only the HHRz loop structure (MS2-B series). In
these device designs, ligand binding results in formation and
breaking of base pairs in a HHRz loop for ON and OFF
switches, respectively (Figure 2B). One drawback of these
transmitter loop-displacing ON switch designs is that they
rely on ligand binding modulating a base pairing interac-
tion within the aptamer sequence, which may not be gener-
ally extendable to other ligand-aptamer pairs and requires
specific information about the ligand-aptamer interaction.
However, similar protein-binding aptamers have been char-
acterized (66,67), which should be readily amendable to this
loop-displacing transmitter strategy.
Through our in vitro SPR-based screening strategy we
identified RNA devices that were functional in yeast
and mammalian cells. As has been observed with small
molecule-responsive RNA devices (23), we found that in
vitro gel-determined cleavage time constants assayed at 500
MMg2+ were well correlated with in vivo gene-regulatory
activities in yeast cells (Figure 6B). The RNA device gene-
regulatory activities in mammalian cells did not signifi-
cantly correlate to in vitro cleavage activities assayed at 500
MMg2+ (Supplementary Figure S7), but didwith cleavage
activities measured at lower Mg2+ concentrations (200 M;
Figure 6F). Our observations suggest a variation in Mg2+
concentration between yeast and (HEK293) mammalian
cells that is significant for HHRz and ribozyme-based de-
vice activities, which have been reported to exhibit differ-
ent cleavage activity profiles at varying Mg2+ levels (53). As
such, for the RNA devices tested in both yeast (Figure 4)
and mammalian cells (Figure 5), which encompass five dif-
ferent transmitter sequences, we do not find significant cor-
relation between gene-regulatory activities between the two
cell types. This finding is in contrast to earlier studies with
small molecule-responsive RNA devices, which observed
gene-regulatory activities in yeast and mammalian cells to
be correlated (15). However, in this earlier study, RNA de-
vices with only three different transmitter sequences were
compared. If we remove one of the transmitter sequences
from our analysis (i.e. both MS2-A1, A2), we also observe
the regulatory activities between yeast andmammalian cells
to be correlated. These findings highlight the importance of
screening and characterizing in vitro device parameters un-
der assay conditions that are reflective of the physiological
conditions of the specific cell type desired for in vivo deploy-
ment.
Our results also demonstrate that the protein-responsive
ribozyme switches are a unique class of RNA devices that
can respond to ligand in either the nucleus or cytoplasm.
This property is somewhat surprising for an ON switch,
which cleaves in the absence of ligand. Depending on the
relative rates of transcription, mRNA export and ribozyme
cleavage, one might expect an ON switch to either cleave
during or immediately after transcription if ligand is absent
from the nucleus, or to cleave after nuclear export if ligand is
absent from the cytoplasm. However, our data suggest that
the ribozyme switches do not cleave substantially before nu-
clear export when ligand is present in only the cytoplasm,
nor do they cleave substantially in the cytoplasm when the
ligand is present in only the nucleus. A possible explana-
tion for the observed activity with cytoplasmic-localized lig-
and is that ribozyme cleavage in the nucleus is low, possibly
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due to prevention of proper HHRz folding due to the bind-
ing of proteins that form the messenger ribonucleoprotein,
thereby reducing ribozyme cleavage prior to export of the
transcript from the nucleus and exposure to the ligand. A
possible explanation for the observed activity with nuclear-
localized ligand is that the ligand binds the mRNA in the
nucleus and remains bound to the mRNA during and af-
ter export. The ability of mRNA harboring an MS2 ap-
tamer to carry the ligand out of the nucleus has been pre-
viously demonstrated (39). While dissociation of the ligand
from the ribozyme switch in the cytoplasm is expected to
be favored in this situation, a slow koff and conformational
switching rate would contribute to providing sufficient time
for the mRNA to be translated before cleavage can occur.
Future experiments could further examine the mechanism
of action of ribozyme switches, by studying the in vivo re-
sponse of switches exhibiting a range of kinetic dissociation
rates, cleavage rates and conformational switching rates to
localized ligands.
Ribozyme-based devices have become an important class
of gene-control elements in synthetic biology, with demon-
strated applications ranging from enzyme evolution, to gene
therapy, to cellular therapeutics (20–21,68). Our studies
provide an important contribution to the growing body of
work on ribozyme-based devices by extending the class of
ligands these RNA devices can detect to proteins and un-
covering the unique capability of these RNA devices to re-
spond to ligand in both the nuclear and cytoplasmic com-
partments. While we demonstrate switches that respond to
MS2 and variant proteins, extension of this platform to di-
verse protein ligands by leveraging existing RNA aptamer-
protein pairs will be an important next step. Such future ef-
forts to continue to develop and leverage this flexible gene-
control platform will be important for extension to applica-
tions requiring the detection of diverse biomarkers, such as
novel diagnostic tools and genetic systems for controlling
cellular behavior in response to those biomarkers.
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